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Previewscreates ER stress that mimicks ‘‘terminal’’
and not ‘‘adaptive’’ UPR, activating the
RIDD mode of IRE1a. Because this
mode of activity arises even at low multi-
plicity of infection (Bronner et al., 2015),
yet without activation of cell death path-
ways during virulent Brucella infection
(Celli and Tsolis, 2015), perhaps Brucella
infection changes the quality of the host
cell UPR. What protein interactions un-
derlie such quality changes still remains
to be determined.
The involvement of IRE1a in activating
NLRP3 upstream of the caspase-2 and
Bid cleavages provides a novel functional
connection between the ER and mito-
chondria. Such a functional interaction
is often thought of in terms of mitochon-
drial-associated-membranes (MAMs),
which are areas of contact between the
two organelles. In fact, Zhou et al. showed
that NLRP3 is associated with the ER and
moves tomitochondria (Zhou et al., 2011).
Perhaps the relocation of NLRP3 is amanifestation of the function of MAMs in
either sensing or causing mitochondrial
dysfunction?
While Brucella abortus infection selec-
tively activates the IRE1a pathway of the
UPR, the data of Bronner et al. bring to
mind the possible activation of inflamma-
somes via one of the other UPR sensors.
The PERK pathway of the UPR has
already been invoked through its tran-
scription factor, ATF5 (Oslowski et al.,
2012), which promotes inflammasome
activation by upregulating TXNIP expres-
sion. Because different inflammasomes
are employed in response to distinct stim-
uli, it is likely that infections by virulent
bacteria activate multiple inflammasomes
and by more than one UPR pathway.REFERENCES
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TREX1 regulates innate immune responses by counteracting DNA accumulation in the cytosol. In this issue of
Immunity, Hasan et al. (2015) show that TREX1 also safeguards the cell against free glycan build-up in the
endoplasmic reticulum, thereby preventing glycan-induced inflammation.Nucleic acid sensors of the innate im-
mune system alert to the presence of
pathogens, in particular of viruses. In
response, type I interferon (IFN), the key
antiviral cytokine, as well as other pro-in-
flammatory mediators are secreted,
which in turn induce the transcription of
multiple interferon inducible genes
(ISGs). Due to genetic predisposition,
some individuals are prone to erroneous
or excessive reactivity to their own nucleic
acids, which leads to autoimmune pathol-
ogies characterized by chronic ISG signa-
tures (Crow and Manel, 2015). Recentyears have seen immense progress in un-
raveling nucleic acid receptors and their
signaling pathways, and many of the
gene variants associated with ISG-driven
autoimmune syndromes have been iden-
tified (Crow and Manel, 2015).
In this context, mutations in three prime
repair exonuclease 1 (TREX1) were the
first identified monogenetic cause of se-
vere lupus (Lee-Kirsch et al., 2007) as
well as of the rare autoimmune diseases
Aicardi Goutie`res syndrome and retinal
vasculopathy with cerebral leukodystro-
phy (RVCL) (Richards et al., 2007).TREX1 functions as one of the three
major DNA-degrading nucleases and
has been shown to prevent the build-up
of immune stimulatory DNA in the cytosol
(Stetson et al., 2008), thus acting as a
critical negative regulator of the cGAMP
synthase (cGAS) signaling pathway
(Gray et al., 2015). Therefore, compared
to other monogenetic and complex ge-
netic causes of autoimmune inflamma-
tion, the physiological role of TREX1 and
the mechanisms leading to immune pa-
thology are considered comparably well
understood.ptember 15, 2015 ª2015 Elsevier Inc. 411
Figure 1. The Dual Immune-Regulatory Role of Exonuclease TREX1
Endogenous or pathogen-derived DNA that enters the cytosol is promptly degraded by TREX1. Patients
with DNase-defective TREX1 develop autoimmune disease, including familial chilblain lupus (FCL) and
Aicardi Goutie`res syndrome (AGS) that are characterized by cytosolic DNA accumulation, which in turn
leads to chronic activation of the cGAMP synthase (cGAS) signaling pathway, resulting in pathologically
elevated type I IFN. With its C terminus, TREX1 spans the ER membrane and interacts with the oligosac-
charyl transferase (OST) complex. Here, TREX1 quality controls N-linked protein glycosylation by prevent-
ing erroneous hydrolysis of the lipid-linked oligosaccharide (LLO) precursor. In patients suffering from
retinal vasculopathy with cerebral leukodystrophy (RVCL), TREX1 frame-shift mutations exclusively affect
the latter function. RVCL pathology is characterized by the build-up of free glycans, which leads to the acti-
vation of an unknown innate immune receptor that promotes excessive production of the inflammatory
chemokine CXCL10 in a tank binding kinase 1 (TBK1)-dependent fashion. By replicating themost frequent
nuclease or C-terminal mutations found in humans, two newly generated genetically targeted mouse
models now allow for the differential investigation of both TREX1 pathway deficiencies.
Immunity
PreviewsHowever, in this issue of Immunity, Ha-
san et al. (2015) report a previously
unrecognized function of TREX1 as a
guarantor of N-linked protein glycosyla-
tion. The group has shown that the
C terminus of TREX1 traverses the endo-
plasmic reticulum (ER) membrane and
directly interacts with components of
the oligosaccharyl transferase (OST)
complex that transfers complex sugars
(glycans) from a lipid-linked oligosaccha-
ride (LLO) precursor onto nascent protein
strands in the ER (Figure 1). Both in iso-
lated cells and in various tissues in vivo,
Hasan et al. (2015) have demonstrated
that, in the absence of TREX1, erroneous412 Immunity 43, September 15, 2015 ª2015hydrolysis of LLO leads to a several
fold increase in free glycans, a mixture
of LLO hydrolysis and degradation
products. Overexpression of nuclease-
mutated full-length TREX1 or of the C
terminus alone are both able to normalize
free glycan amounts, indicating that not
the cytosolic exonuclease but rather the
ER-localized portion of TREX1 is respon-
sible for regulating N-glycosylation. The
group then has proceeded to show that
free glycans purified from TREX1-defi-
cient cells were immune stimulatory for
macrophages and upregulated the in-
flammatory chemokine CXCL10 and
other ISGs but not type I IFN. These find-Elsevier Inc.ings were in line with the group’s previ-
ous observation of interferon-indepen-
dent activation of antiviral genes (Hasan
et al., 2013).
The same CXCL10-dominated ISG
signature in the absence of type I IFN is
also observed in patients suffering from
RVCL. In RVCL patients, TREX1 lacks
the ER-localized C terminus as a conse-
quence of frame-shift mutations. The au-
thors have shown that such mutations
do not affect TREX1 nuclease activity
but exclusively promote the accumulation
of free glycans. Hasan et al. (2015) hy-
pothesize that this is due to improper
functioning of the OST complex and
indeed find that in cells derived from
RVCL patients, the OST inhibitor aclaci-
nomycin (Acm) is able to efficiently reduce
both free glycan accretion as well as the
glycan-induced CXCL10 immune signa-
ture. These findings also hold true in vivo.
Due to chronic inflammation in particular
of the heart and liver, TREX1-deficient
mice show limited viability. Intriguingly,
Acm treatment of TREX1-deficient mice
reduced the ISG signature, normalized
liver and spleen morphology, and
improved viability. In addition, a geneti-
cally targeted mouse model has recently
been generated that recapitulates the
most frequent human TREX1 mutation
leading to the production of nuclease-
inactive TREX1 protein (Grieves et al.,
2015). However, in this TREX1 variant,
the glycan-regulating function of TREX1
in the ER presumably remains intact,
and, along with a milder course and a
much later onset of autoimmune symp-
toms, these mice show improved viability
compared to fully TREX1-deficient mice
(Grieves et al., 2015).
Altogether, this indicates that glycan
regulation constitutes a key function of
TREX1 and that deregulation of this
pathway notably contributes to the severe
immune pathology of TREX1-deficient
mice, as well as to that of human RVCL
patients.
In order to study TREX1 glycan regula-
tion independent of its nuclease function,
Hasan et al. (2015) generated a new
mouse model of RVCL by placing the hu-
man TREX1-V235fs mutant allele under
the control of the endogenous murine
promoter. Primary myeloid cells of these
mice that are heterozygous carriers of
this allele show elevated glycans, as
well as chronic CXCL10 and other ISG
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Previewsexpression, with a more pronounced
phenotype in TREX1-V235fs homozy-
gotes. Although these mice showed
normal viability and did not develop overt
tissue inflammation, older mice devel-
oped far more autoantibodies than WT
mice of the same age. Future studies
with this model will reveal whether OST
inhibition by Acm is able to suppress
autoantibody formation.
Given that TREX1 expression varies
widely between cell types and activation
states, the exact role of TREX-mediated
regulation of N-glycosylation bears
further investigation. Is TREX1 required
to maintain general glycan homeostasis,
or might it play a role in compensating
for scenarios of cellular distress, or of in-
fections? Although the innate immune
sensing of fungal and bacterial glycans
via toll-like receptors TLRs 2 and 4 or
the NOD-like receptors is well under-
stood, the data presented by Hasan
et al. (2015) for the first time implicate
endogenous free glycans as innate im-
mune stimuli. However, the precise nature
of the free self-glycan(s) that demonstrate
immune activity remains to be estab-
lished. The authors also do not identify
which innate immune receptor(s) initiate
the response to free glycans. This is not
surprising given the sheer multitude of
complex sugar-sensing immune recep-
tors (Rabinovich et al., 2012). On the other
hand, the authors’ finding that free glycan
sensing is independent of cGAS andstimulator of interferon genes (STING)
yet dependent on tank-binding kinase 1
(TBK1) dramatically narrows down the
options, because this should already
exclude a number of candidates, in-
cluding all currently known C-type lectin
receptors.
Our growing mechanistic understand-
ing of ISG-driven autoinflammatory con-
ditions has fueled the interest to therapeu-
tically antagonize deregulated nucleic
acid sensing pathways (Junt and Barchet,
2015). Hasan et al. (2015) now highlight a
role for the innate immune sensing of
endogenous complex sugars and estab-
lish that drugs that act by modulating
free glycans, such as Acm, might hold
therapeutic promise for RVCL and
possibly also for patients suffering from
other autoimmune disorders.
To derive meaning from complexity, the
reductionist approach to science gener-
ally serves us quite well. Yet once an
immune function is paradigmatically es-
tablished—as is the case for the TREX1
nuclease activity—it is tempting to as-
sume that all observed defects are
caused by variations of the same patho-
mechanism. This might at times lead us
to behave like the proverbial blind men
who try to describe an elephant by
focusing exclusively on the prominent
feature that is encountered first. In their
seminal paper, Hasan et al. (2015) boldly
approach from a different angle, discover
TREX1’s sweet tooth, and thus demon-Immunity 43, Sestrate that also in the case of TREX1, we
are only beginning to see the whole
elephant.REFERENCES
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